Sol Gel Technologies Ltd (SLGL) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · United States · ISIN IL0011417206
Sol Gel Technologies Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 11.54 m USD | 19.39 m USD |
| Gross profit | 11.54 m USD | 19.39 m USD |
| Operating income | -12.01 m USD | -7.54 m USD |
| EBIT | -12.01 m USD | -7.54 m USD |
| Net income | -10.58 m USD | -6.13 m USD |
| Diluted EPS – continuing operations | -3.80 USD | -2.20 USD |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
More stocks
- Media Capital (MCP.LS)
- Justem Co., Ltd. (417840.KQ)
- PETCHSRIVICHAI ENTERPRISE PUBLIC COMPANY LIMITED (PCE.BK)
- Wei Chuan Foods Corp (1201.TW)
- ASIX Electronics (3169.TWO)
- KCG Corporation Public Company Limited (KCG.BK)
- Archer Limited (ARCH.OL)
- Olympia Financial Group Inc (OLY.TO)
- Silver Bow Mining Corp. (SBMT)
- Premia S.A. (PREMIA.AT)
- Staude Capital Global Value Fund Ltd (GVF.AX)
- SCI Pharmtech Inc (4119.TW)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.